Reliance Acquires Majority Stake in Scentech, Expanding into Health-Tech Sector
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Benzinga
- Acquisition Announcement: Reliance Global Group has announced the acquisition of a majority stake in Israeli diagnostics company Scentech, marking its first investment in the health-tech ecosystem, despite none of Scentech's products being commercially approved yet.
- Strategic Positioning: This acquisition will serve as the inaugural asset for Reliance's newly established technology investment arm, Ezra International Group, indicating the company's commitment to the health-tech sector and its potential for future growth.
- Market Reaction: Following the announcement, Reliance's stock fell by 4.93% to $0.58, reflecting market caution regarding the acquisition and potentially impacting the company's short-term stock performance.
- Future Outlook: CEO Ezra Beyman stated that through the acquisition of Scentech, Reliance aims to expand its influence in the health-tech field, which, if successfully developed and commercialized, could provide new growth opportunities for the company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
